caa a22 4500 605491836 CHVBK 20210128100512.0 cr unu---uuuuu 210128e20150401xx s 000 0 eng 10.1007/s10147-014-0707-1 doi (NATIONALLICENCE)springer-10.1007/s10147-014-0707-1 Low PTEN expression is associated with worse overall survival in head and neck squamous cell carcinoma patients treated with chemotherapy and cetuximab [Elektronische Daten] [Alexandre da Costa, Felipe D'Almeida Costa, Adriana Ribeiro, Andréia Guimarães, Ludmila Chinen, Clóvis Lopes, Vladmir de Lima] Background: Platinum-based chemotherapy associated with cetuximab is the first-line treatment for inoperable recurrence or metastatic head and neck squamous cell carcinoma (HNSCC). There is no established biomarker for cetuximab efficacy in HNSCC. The PI3K pathway is one of the most frequently altered pathways in HNSCC. Loss of phosphatase and tensin homolog (PTEN) expression occurs in up to 30% of cases. Methods: This was a retrospective analysis of data from 61 patients with inoperable recurrence or metastatic HNSCC treated with cetuximab. PTEN, epidermal growth factor receptor and p16 expression were analyzed by immunohistochemistry and tested for association with clinical outcomes. Results: Median overall survival was 11.4months and progression-free survival was 6.9months. Low PTEN expression was present in 26.2% of patients and identified patients with worse prognosis. p16 was positive in only 8.5% of tumors. Conclusions: Low PTEN expression in patients treated with cetuximab plus chemotherapy emerged as a prognostic biomarker and should be evaluated for its predictive role for cetuximab efficacy. Japan Society of Clinical Oncology, 2014 PTEN nationallicence p16 nationallicence Cetuximab nationallicence Head and neck cancer nationallicence Biomarker nationallicence Prognosis nationallicence da Costa Alexandre Medical Oncology Department, Fundação Antonio Prudente, AC Camargo Cancer Center, 211 Professor Antonio Prudente Street, Liberdade, 01509-900, São Paulo, SP, Brazil aut D'Almeida Costa Felipe Pathology Department, Fundação Antonio Prudente, AC Camargo Cancer Center, 211 Professor Antonio Prudente Street, Liberdade, 01509-900, São Paulo, SP, Brazil aut Ribeiro Adriana Medical Oncology Department, Fundação Antonio Prudente, AC Camargo Cancer Center, 211 Professor Antonio Prudente Street, Liberdade, 01509-900, São Paulo, SP, Brazil aut Guimarães Andréia Medical Oncology Department, Fundação Antonio Prudente, AC Camargo Cancer Center, 211 Professor Antonio Prudente Street, Liberdade, 01509-900, São Paulo, SP, Brazil aut Chinen Ludmila Medical Oncology Department, Fundação Antonio Prudente, AC Camargo Cancer Center, 211 Professor Antonio Prudente Street, Liberdade, 01509-900, São Paulo, SP, Brazil aut Lopes Clóvis Pathology Department, Fundação Antonio Prudente, AC Camargo Cancer Center, 211 Professor Antonio Prudente Street, Liberdade, 01509-900, São Paulo, SP, Brazil aut de Lima Vladmir Medical Oncology Department, Fundação Antonio Prudente, AC Camargo Cancer Center, 211 Professor Antonio Prudente Street, Liberdade, 01509-900, São Paulo, SP, Brazil aut International Journal of Clinical Oncology Springer Japan 20/2(2015-04-01), 282-289 1341-9625 20:2<282 2015 20 10147 https://doi.org/10.1007/s10147-014-0707-1 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s10147-014-0707-1 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- da Costa Alexandre Medical Oncology Department, Fundação Antonio Prudente, AC Camargo Cancer Center, 211 Professor Antonio Prudente Street, Liberdade, 01509-900, São Paulo, SP, Brazil aut NATIONALLICENCE 700 1- D'Almeida Costa Felipe Pathology Department, Fundação Antonio Prudente, AC Camargo Cancer Center, 211 Professor Antonio Prudente Street, Liberdade, 01509-900, São Paulo, SP, Brazil aut NATIONALLICENCE 700 1- Ribeiro Adriana Medical Oncology Department, Fundação Antonio Prudente, AC Camargo Cancer Center, 211 Professor Antonio Prudente Street, Liberdade, 01509-900, São Paulo, SP, Brazil aut NATIONALLICENCE 700 1- Guimarães Andréia Medical Oncology Department, Fundação Antonio Prudente, AC Camargo Cancer Center, 211 Professor Antonio Prudente Street, Liberdade, 01509-900, São Paulo, SP, Brazil aut NATIONALLICENCE 700 1- Chinen Ludmila Medical Oncology Department, Fundação Antonio Prudente, AC Camargo Cancer Center, 211 Professor Antonio Prudente Street, Liberdade, 01509-900, São Paulo, SP, Brazil aut NATIONALLICENCE 700 1- Lopes Clóvis Pathology Department, Fundação Antonio Prudente, AC Camargo Cancer Center, 211 Professor Antonio Prudente Street, Liberdade, 01509-900, São Paulo, SP, Brazil aut NATIONALLICENCE 700 1- de Lima Vladmir Medical Oncology Department, Fundação Antonio Prudente, AC Camargo Cancer Center, 211 Professor Antonio Prudente Street, Liberdade, 01509-900, São Paulo, SP, Brazil aut NATIONALLICENCE 773 0- International Journal of Clinical Oncology Springer Japan 20/2(2015-04-01), 282-289 1341-9625 20:2<282 2015 20 10147